Summit Therapeutics (SMMT) EBITDA (2016 - 2025)
Historic EBITDA for Summit Therapeutics (SMMT) over the last 9 years, with Q3 2025 value amounting to -$231.8 million.
- Summit Therapeutics' EBITDA fell 31337.42% to -$231.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$922.0 million, marking a year-over-year decrease of 36906.76%. This contributed to the annual value of -$221.2 million for FY2024, which is 6406.85% up from last year.
- As of Q3 2025, Summit Therapeutics' EBITDA stood at -$231.8 million, which was down 31337.42% from -$565.9 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' EBITDA registered a high of -$17.9 million during Q4 2022, and its lowest value of -$565.9 million during Q2 2025.
- In the last 4 years, Summit Therapeutics' EBITDA had a median value of -$56.1 million in 2024 and averaged -$107.2 million.
- Per our database at Business Quant, Summit Therapeutics' EBITDA skyrocketed by 130.63% in 2023 and then tumbled by 83792.49% in 2025.
- Quarter analysis of 4 years shows Summit Therapeutics' EBITDA stood at -$17.9 million in 2022, then tumbled by 104.93% to -$36.7 million in 2023, then tumbled by 66.74% to -$61.2 million in 2024, then tumbled by 278.8% to -$231.8 million in 2025.
- Its last three reported values are -$231.8 million in Q3 2025, -$565.9 million for Q2 2025, and -$63.2 million during Q1 2025.